Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

The 10 Most-Watched Australian Movies of 2026 So Far, From Elvis Concert Films to Zombie Thrillers

Published

on

EPiC: Elvis Presley in Concert
EPiC: Elvis Presley in Concert
EPiC: Elvis Presley in Concert

Australian filmmakers have delivered one of the most varied slates of homegrown cinema in recent memory so far in 2026, spanning family animation, zombie horror, concert documentaries and Indigenous drama, even as local audiences continue to favor streaming platforms over cinemas for many of the year’s biggest Aussie-made titles. Here is a look at 10 of the most-watched Australian films of the year to date, based on box office performance, streaming popularity and critical attention.

EPiC: Elvis Presley in Concert. Baz Luhrmann’s latest ode to the King of Rock ‘n’ Roll stands as the highest-performing homegrown release at the Australian box office so far in 2026, by a significant margin over every other local production. Built around meticulously restored live footage of Elvis Presley, the film has drawn strong turnout from audiences eager for the kind of imported-star validation that has historically boosted Australian films at the box office, even though Presley himself never performed in Australia.

The Pout-Pout Fish. Sitting just behind EPiC as the second-highest-performing Australian release of the year, this colourful family animation from Brisbane-based studio Like a Photon Creative adapts the popular children’s book of the same name and kicked off the year’s slate of local releases.

We Bury the Dead. Directed by Zak Hilditch and starring Daisy Ridley alongside Brenton Thwaites, this Tasmanian-set zombie thriller has emerged as one of the year’s most talked-about genre entries, following an American woman collecting corpses amid a post-accident zombie outbreak. The film premiered at South by Southwest before its Australian theatrical rollout in February and has drawn praise for its blend of horror and dark comedy set against the Tasmanian landscape.

War Machine. A Victoria-shot science-fiction action film pitting soldiers against robots, War Machine features Australian director Patrick Hughes, co-writer James Beaufort, and cast members including Jai Courtney, Keiynan Lonsdale and Daniel Webber. Despite an $80 million U.S. budget, the film earned just $82,000 at the Australian box office during its brief theatrical run, illustrating a broader trend this year: Australian audiences have overwhelmingly preferred watching Aussie-shot productions like War Machine from their couches on Netflix rather than in cinemas.

Advertisement

Bring Her Back. From brothers Danny and Michael Philippou, following up their breakout horror hit “Talk to Me,” Bring Her Back claimed the Best Film honor at the 2026 AACTA Awards, cementing the Philippou brothers as two of the most closely watched genre filmmakers currently working in Australian cinema.

The Deb. Rebel Wilson’s directorial debut, adapting the acclaimed stage musical by Hannah Reilly and Megan Washington, overcame production delays and legal controversy to become a genuine crowd-pleaser upon its April release. Set in a fictional country town, the film follows cousins clashing in the lead-up to a debutante ball, blending big laughs and pop-inflected musical numbers with a distinctly Australian sense of humor and local flavor.

Wolfram. Widely regarded as one of the standout Australian films of the year, Wolfram is a spiritual successor to Warwick Thornton’s acclaimed “Sweet Country” and continues the celebrated Indigenous filmmaker’s exploration of colonial violence and its lasting impact, dating back to his Cannes Caméra d’Or-winning debut, “Samson and Delilah.” Critics have singled out Thornton’s cinematography as demanding to be seen on the biggest screen possible.

Alphabet Lane. Among the strongest new releases of the year, this debut feature from first-time filmmaker James Litchfield stars Tilda Cobham-Hervey and strands its characters against the outback landscape, offering what reviewers described as a playful and unexpectedly original exploration of long-term relationships, loneliness and the difficulty of making friends as an adult, avoiding the sameness sometimes associated with outback-set Australian films.

Advertisement

Jimpa. Sophie Hyde’s heartfelt drama stars John Lithgow and Olivia Colman and has drawn attention as one of the year’s most emotionally resonant Australian releases, adding to a 2026 slate that has spanned everything from horror and comedy to intimate family drama.

Apex, The Bluff and Balls Up. Rounding out the year’s most-watched Aussie-shot content are a trio of major streaming titles that, while not all technically classified as Australian productions given their international financing and creative teams, have nonetheless dominated local streaming charts. Apex, a Netflix survivalist thriller blending elements of a serial-killer story and starring Taron Egerton in an Australian accent, has become one of the platform’s most-watched titles domestically. Prime Video’s swashbuckling adventure The Bluff and Mark Wahlberg comedy Balls Up, both filmed in Queensland, have similarly drawn strong local streaming numbers, reflecting how Australian audiences are increasingly encountering Aussie-filmed content through their couches rather than at the cinema.

Beyond this list, several other Australian titles have drawn critical acclaim and audience attention throughout 2026, including the Teresa Palmer-led romantic comedy Addition, the Lismore flood documentary Floodland, the Mental As Anything documentary Live It Up, sailing documentary True South, horror debut Proclivitas, Mongolia-set documentary Iron Winter, World War II documentary Under a Bamboo Sky, the fight drama Beast starring Daniel MacPherson and Russell Crowe, and Seven Snipers, featuring Radha Mitchell and Tim Roth.

Industry analysts have continued to push back on the long-standing narrative that Australian films struggle at the box office because they all resemble one another, pointing to 2026’s slate as clear evidence to the contrary. Over the course of just a few months, local filmmakers have delivered family animation, romantic comedy, undead horror, Elvis concert footage, queer family drama, Indigenous historical drama and documentary work spanning band biography, natural disaster and rural Mongolia, a level of genre diversity industry observers say rivals any comparable stretch in recent Australian film history.

Advertisement

Despite that variety, Hollywood productions continue to dominate Australia’s overall box office rankings for 2026, with only a handful of homegrown or Australian-adjacent titles, including EPiC, The Pout-Pout Fish, and international productions featuring prominent Australian actors such as Wuthering Heights, Song Sung Blue and Crime 101, cracking the year’s top 20 releases. Even so, industry figures say the strength and range of this year’s Australian film slate suggests local audiences have more reason than ever to support homegrown cinema in theaters, rather than waiting to catch Aussie-made films once they arrive on streaming platforms months later.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Globant: A Strong Way To Play The ‘Software Isn’t Dead’ Case (NYSE:GLOB)

Published

on

Globant: A Strong Way To Play The 'Software Isn't Dead' Case (NYSE:GLOB)

This article was written by

I’ve been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a small, tech-focused retail brokerage in NYC. Now co-host of The Atlantic Current podcast, with twice-weekly cross-border conversations on politics, finance, and culture.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GLOB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Aurelia Metals Limited 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:AUMTF) 2026-07-19

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Business

Jobs data tops economic agenda as Iran war re-escalates

Published

on

Jobs data tops economic agenda as Iran war re-escalates

Resilient jobs data is a bright spot for Australia’s economy but the longer the Middle East conflict drags on, the worse the prospect for growth and inflation.

Continue Reading

Business

Netflix: The Market Isn’t Giving Enough Respect To The Streaming Giant (Upgrade) (NFLX)

Published

on

Netflix: The Market Isn't Giving Enough Respect To The Streaming Giant (Upgrade) (NFLX)

This article was written by

JR Research is an opportunistic investor. I was recognized by TipRanks as a Top Analyst, and also by Seeking Alpha as a “Top Analyst To Follow” for Technology, Software, and Internet, as well as for Growth and GARP. I identify attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. My picks have consistently demonstrated market outperformance over time. My approach combines timely and sharp price action analysis with fundamentals as my foundation. I also tend to avoid overhyped and overvalued stocks while capitalizing on battered stocks with significant upside recovery possibilities. I run the investing group Ultimate Growth Investing which specializes in identifying high-potential opportunities across various sectors. My main ideas revolve around stocks with strong growth potential, and also well-beaten contrarian plays. I designed the group for investors seeking to capitalize on growth stocks with solid fundamentals, robust buying momentum, and appealing turnaround plays to generate alpha consistently. Learn more

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SPY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

CG Oncology Stock: Priced To Perfection On Future Pipeline Success (NASDAQ:CGON)

Published

on

CG Oncology Stock: Priced To Perfection On Future Pipeline Success (NASDAQ:CGON)

This article was written by

I started my investing journey at age 18, and over the years, I have developed a disciplined strategy that has consistently outperformed the broader market. My approach to the market is twofold. For short-term tactical opportunities, I focus on value plays—identifying fundamentally sound stocks that have been unfairly beaten down by market overreactions, buying the dip, and capturing the upside as the price recovers. For the long term, I anchor my portfolio with proven compounders that exhibit durable growth, healthy financials, and strong competitive advantages. Beyond managing my personal portfolio, I am deeply passionate about financial education. I created a comprehensive online course to help beginners navigate the mechanics of the stock market, and I am currently partnering with a team to build a dedicated educational website for new retail investors. Whether I am analyzing a quick turnaround play or a decade-long hold, my goal is always to uncover clear, actionable value.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Published

on


Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

Continue Reading

Business

Long-term investment case for India remains very strong: Kevin Foley, co-head of global investment banking at J.P. Morgan

Published

on

Long-term investment case for India remains very strong: Kevin Foley, co-head of global investment banking at J.P. Morgan
J.P. Morgan sees India as a priority market, driven by strong growth, deepening capital markets and rising global relevance, said Kevin Foley, co-head of global investment banking at J.P. Morgan, speaking with Kairavi Lukka and Sangita Mehta.

Oil remains the key near-term risk, though India is better placed than in previous cycles to absorb price volatility, he said. Foley said India’s long-term investment case remains intact despite forieign outflows, valuation concerns and global uncertainty. Edited excerpts.

What is J.P. Morgan’s growth strategy for India, particularly in investment banking?

India is a priority market for us. We are adding to our local team, across product and coverage roles, and we are continuing to grow. The trajectory has been upward, and we expect that to continue. Our ambition for Global Investment Banking is to be number one across markets, products, and regions, including in India.

Advertisement

Why is India such a priority?


Simply put: 7% GDP growth. India is one of the most compelling long-term growth stories anywhere in the world. It combines economic growth, deepening capital markets, a rapidly expanding corporate sector, and increasing global relevance. The talent – within our team and in India’s entrepreneurship – have been key drivers to us investing in the region for more than 80 years.
After the rally this year, how should investors think about AI valuations now?Valuations are pricing in accelerated growth. Whether those valuations are too high or too low will only be known in hindsight. If the growth comes through, people will not talk about these as peak valuations. If adoption takes longer, then one could argue that valuation multiples were ahead of themselves. The question is not whether AI will deliver on the growth story. It’s not an “if”. It’s a matter of when and how quickly.

How is this AI cycle different from the dot-com boom?

AI has a broader potential impact on society – both in the way we work and the way we live. Companies aren’t just investing in the promise of AI – they’re deploying it to improve productivity, reduce costs and create new revenue streams. People talk about efficiency gains and shorter work weeks. Whether that plays out over a longer period is a separate question, but the potential impact is much bigger. It’s more transformative than the internet. The internet changed the way people consume. It changed how we shop, read newspapers or order food. AI is a broader, durable transformation across industries.

Foreign investors have been sellers in India. What could bring them back?

Advertisement

Long-term investment case for India remains very strong. Foreign capital will always move around depending on global opportunities and valuations. We saw that with China. Its stimulus programme and the valuation gap between markets saw global money move there. But as India’s growth proves sustainable, money should come back. We have already seen foreign outflows decline. The rupee has also had an impact, but those seem to have stabilised.

Were valuations one reason foreign investors held back?

Some other markets are more concentrated in terms of where value creation is coming from. That needs to be factored in when comparing them with India’s broader market. India has seen multiples correct over the past 18 months. Ultimately, markets are efficient in making decisions.

At current levels, do you think India is overvalued?

Advertisement

On a relative basis, India has had a significant correction, while growth prospects remain good.. At the same time, the macro story has not changed. The one uncertainty is the Strait of Hormuz and its impact on oil.

How big a risk is oil for India?

It is a global factor, but global factors have different regional impacts. The impact here is more acute than in other markets because India is one of the world’s largest oil importers. Our view is that India can handle higher oil prices than current levels. Compared to previous cycles, it’s entered this period with stronger fundamentals, larger FX reserves and a more diversified energy import strategy, making it better equipped to absorb volatility. What would be more problematic is an escalation that creates a sustained supply shock.

How do you see appetite for large IPOs in India amid global uncertainty?

Advertisement

Investors are taking an optimistic view that geopolitical issues and the energy situation will be resolved. There has been almost $20 billion of activity across IPOs, follow-ons and other equity raising this year, and we believe activity can increase in the second half. Market volatility may impact timing, but it doesn’t change the long-term investment case for India.

Continue Reading

Business

Alphabet, Intel in focus as US earnings season gathers steam

Published

on

Alphabet, Intel in focus as US earnings season gathers steam
New York: US corporate earnings season gathers steam in the coming week as Alphabet and Intel are set to offer updates that could sway the market-leading AI trade amid high profit expectations and Iran war uncertainty.

The S&P 500 skidded on Friday to post a weekly decline, dragged down by a steep pullback in high-flying semiconductor shares. Still, the benchmark S&P 500 remained up about 9% in 2026, and stood 2% below its early June record high. Alphabet’s quarterly report on Wednesday will command Wall Street’s attention. AI capex has been at the heart of this year’s market rally.

Continue Reading

Business

Titan International: Industry Weakness Offsets A Cheap Valuation

Published

on

Titan International: Industry Weakness Offsets A Cheap Valuation

Titan International: Industry Weakness Offsets A Cheap Valuation

Continue Reading

Business

My fitness tracker knew I was pregnant before I did

Published

on

Graphic representing sunshine with blue sky behind

Dr Stuart Lavery, consultant of reproductive medicine at University College Hospital in London, said: “People are understandably using this technology to try to get a greater understanding, and to try and pick up things as early as possible because it has such a profound impact on your life if you’re planning a pregnancy.”

However, “we might be running before we can walk,” he cautioned.

“We probably need a lot more data on the reliability, we need a lot more research… otherwise what happens is your levels of anxiety will just skyrocket,” he said.

“I have no doubt that more people will be using technology, an app-based approach or a wearable-based approach, to try and pick up these things. But I think it should come with quite a big health warning about how much we can rely on them for accuracy.”

Advertisement

When asked about the anxiety women reported feeling early in their pregnancy as a result of checking their ring data, Dr Chris Curry, Oura’s clinical director of women’s health, told BBC News: “With or without biometric tracking, pregnancy can be an uncertain time where many women, particularly those pregnant for the first time, are in the dark about the range of what’s normal.”

She added that if women feel overwhelmed, the company “encourages members to take a break from the app experience, whilst Oura Ring continues to collect data and gather insights”, adding: “The ring is a support tool, not a replacement for your care team.”

Ravika sadly did miscarry. She’s hoping to start trying to conceive again soon – and when she does, her experience has made her rethink wearing her tracker again.

“I didn’t really see myself as being an anxious person, but… I think going forward if it came to a point where I had an inkling that I was pregnant and my stats were low, as soon as that positive pregnancy test was there, I do think it would be the best thing for me to take the ring off.”

Advertisement
Continue Reading

Trending

Copyright © 2025